Clinical Trials on Non-small Cell Lung Cancer (NSCLC) in New Zealand

Total 1801 results

Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell Carcinoma

United States
Genentech, Inc.
Flatiron Health, Inc.; Foundation Medicine, Inc.

Completed

Prospective Clinicogenomic Program (PCG)

Non-Small Cell Lung Cancer (NSCLC) | Small-Cell Lung Cancer (SCLC)

United States
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, United Kingdom, Spain
Elephas
Beaufort CRO

Recruiting

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)

NSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | NSCLC, Stage III | Nsclc | NSCLC Stage II

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Minimal Residual Disease | NSCLC Stage IV | Nsclc | Metastatic Non Small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

United States
AstraZeneca

Completed

Osimertinib Study in Indian Patients

Non Small Cell Lung Cancer (NSCLC)

India
Ludwig Institute for Cancer Research
Xcovery Holding Company, LLC; Cancer Research Institute, New York City; MedImmune...

Completed

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Carcinoma | NSCLC | Non-small Cell Lung Cancer

United States
PharmaMar

Completed

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Non-Small Cell Lung Cancer (NSCLC)

United States
Agenus Inc.

Terminated

Study of AGEN1884 With Pembrolizumab in 1L NSCLC

NSCLC Stage IV

New Zealand, Australia
State University of New York - Upstate Medical...

Completed

Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA)

Non-small Cell Lung Cancer (NSCLC)

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK Mutation

United States, Canada
Albert Einstein College of Medicine
Montefiore Medical Center

Active, not recruiting

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial. (SPRINT)

Non-small Cell Lung Cancer, NSCLC

United States
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
Pfizer

Completed

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

United States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
IsoRay Medical, Inc.

Withdrawn

A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer

United States
NYU Langone Health
Bristol-Myers Squibb

Completed

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

United States
Albert Einstein College of Medicine
Celldex Therapeutics

Active, not recruiting

FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer (FLT3)

Non-small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC)

India
Dartmouth-Hitchcock Medical Center
Sanofi; Genentech, Inc.

Completed

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | NSCLC | Non-small Cell Lung Cancer

United States
Yale University
Merck Sharp & Dohme LLC

Completed

Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
Daiichi Sankyo, Inc.

Terminated

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Hoffmann-La Roche

Active, not recruiting

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Metastatic Melanoma | Non-small Cell Lung Cancer (NSCLC) | Solid Tumors | Esophageal Squamous Cell Carcinoma (ESCC) | Small Cell Lung Cancer (SCLC)

United States, Korea, Republic of, Denmark, France, Spain, New Zealand
Amgen

Terminated

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

United States, Austria, Australia
Ludwig Institute for Cancer Research
Boehringer Ingelheim; MedImmune LLC; PharmaJet, Inc.; CureVac; Cancer Research Institute...

Completed

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NSCLC | Metastatic Non-small Cell Lung Cancer

United States
Jeffrey Clarke
Merck Sharp & Dohme LLC; Grid Therapeutics

Suspended

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Metastatic NSCLC | Recurrent Non Small Cell Lung Cancer

United States
Icahn School of Medicine at Mount Sinai

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Non-Small Cell Lung Cancer (NSCLC)

United States
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Taiwan, Japan
Memorial Sloan Kettering Cancer Center

Completed

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). (CONCORDANCE)

NSCLC (Non-small Cell Lung Cancer)

India
Astex Pharmaceuticals, Inc.

Completed

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Non-small Cell Lung Cancer(NSCLC)

United States, Korea, Republic of, Spain, France, Canada
AstraZeneca

Terminated

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1)

Small Cell Lung Cancer | Non-Small Cell Lung Cancer

United States, Taiwan, New Zealand, Spain
OncoMed Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Completed

A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Australia, New Zealand, Spain
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

Non-Small-Cell-Lung Cancer (NSCLC)

United States
Pfizer

Completed

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (ARCHER 1042)

Non Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Switzerland, Australia
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (PRESERVE 4)

NSCLC | Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States
AstraZeneca

Completed

A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients (KINDLE)

Non-small-cell Lung Cancer (NSCLC)

Mexico, Peru, Argentina, Taiwan, India, Thailand, Colombia, Uruguay, Chile, Dominican Republic
University of Pittsburgh
Bristol-Myers Squibb

Completed

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

Non Small Cell Lung Cancer (NSCLC)

United States
MedImmune LLC

Completed

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

NSCLC | Lung Cancer | Non-small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, United Kingdom, Korea, Republic of, Australia, Taiwan
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
Bristol-Myers Squibb

Completed

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)

Non Small Cell Lung Cancer (NSCLC)

United States, Canada
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Canada, Belgium, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Poland
Daiichi Sankyo

Recruiting

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
AbbVie (prior sponsor, Abbott)

Completed

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

NSCLC | Lung Cancer | Non-Small-Cell Lung Cancer

United States, Czech Republic, Greece, Hungary, Netherlands, Slovakia
BeiGene

Terminated

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

China, Australia

Clinical Trials on Non-small Cell Lung Cancer (NSCLC) in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations